Skip to main content
. Author manuscript; available in PMC: 2009 Oct 2.
Published in final edited form as: Am J Physiol Renal Physiol. 2008 Feb 13;294(4):F971–F981. doi: 10.1152/ajprenal.00313.2007

Table 2. Drugs used in this study.

Target Drug Name Abbreviation Source
Nonselective mAChRs agonists Muscarine Musc Sigma, St. Louis, MO
Oxotremorine methiodide OxoM Sigma
Oxotremorine sesquifumarate salt OxoS Sigma
Acetylcholine ACh Sigma
Selective M1 agonist McN-A-343 McN-A-343 Sigma
Nonselective mAChR antagonist Atropine methyl nitrate AMN Sigma
Selective M2 antagonist 11-[[2-[(Diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one AF-DX 116 Tocris, Ellisville, MI
Selective M3 antagonist 4-diphenylacetoxy-N-methylpiperine 4-DAMP Tocris
Nonselective purinergic receptor agonist Adenosine 5′-triphosphate ATP Sigma
Nonselective purinergic receptor antagonist 4-[[4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]azo]-1,3-benzenedisulfonic acid tetrasodium salt PPADS Sigma
PLC inhibitor (1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-2,5-dione) U-73122 Sigma
Inactive analog of the PLC inhibitor (1-[6-[((17β)-3-Methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-2,5-pyrrolidinedione) U-73343 Sigma
Membrane-permeable diacylglycerol analog 1-Oleoyl-2-acetyl-sn-glycerol OAG Sigma
Calcium ionophore Ionomycin Ionomycin Sigma